Peptides derived from type I thrombospondin repeat-containing proteins of the CCN family inhibit proliferation and migration of endothelial cells

International Journal of Biochemistry and Cell Biology

Volumn 39, Issue 12, 2007, Pages 2314-2323

  Karagiannis, Emmanouil D ^a   Popel, Aleksander S ^a  

^a Johns Hopkins University   (United States)

Author keywords

Adamtsostatin like 4; Angiogenesis; Complestatin C6; Connectostatin; Cyrostatin; Endogenous; Endothelial cell; Fibulostatin 6.1; Inhibitors; Migration; Nephroblastostatin; Netrinstatin 5C; Netrinstatin 5D; Proliferation; Spondinstatin 1; Wispostatin 2; Wispostatin 3

Indexed keywords

ADAMTSOSTATIN LIKE 4; ARGINYLALANYLTRYPTOPHYLARGINYLCYSTEINYLVALYLSERYLCYSTEINYLARGINYL GLUTAMINYLSERYLLYSYLARGINYLTHREONYLGLYCYLTRYPTOPHYLASPARAGINYLGLYCYLGLUTAMYL; CCN PROTEIN; COMPLESTATIN C6; CONNECTOSTATIN; CYROSTATIN; CYSTEINYLGLYCYLTRYPTOPHYLTHREONYLLEUCYLPROLYLALANYLTHREONYL GLYCYLARGINYLMETHIONYLVALYLGLYCYLTHREONYLTHREONYLCYSTEINYLSERYLALANYL; FIBULOSTATIN 6 1; FUMAGILLOL CHLOROACETYLCARBAMATE; GENE PRODUCT; NEPHROBLASTOSTATIN; NETRINSTATIN 5C; NETRINSTATIN 5D; PEPTIDE; SERYLALANYLTRYPTOPHYLARGINYLALANYLCYSTEINYLSERYLVALYL THREONYLCYSTEINYLGLYCYLLYSYLGLYCYLISOLEUCYLGLUTAMINYLLYSYLARGINYLSERYLARGINYL; SERYLGLUTAMYLTRYPTOPHYLSERYLASPARTYLCYSTEINYLSERYLVALYLTHREONYL CYSTEINYLGLYCYLLYSYLGLYCYLMETHIONYLARGINYLTHREONYLARGINYLGLUTAMINYLARGINYL; SERYLPROLYLTRYPTOPHYLSERYLGLUTAMINYLCYSTEINYLSERYLVALYLARGINYL CYSTEINYLGLYCYLARGINYLGLYCYLGLUTAMINYLARGINYLSERYLARGINYLGLUTAMINYLVALYLARGINYL; SPONDINSTATIN 1; THREONYLALANYLTRYPTOPHYLGLYCYLPROLYLCYSTEINYLSERYLTHREONYLTHREONYL CYSTEINYLGLYCYLLEUCYLGLYCYLMETHIONYLALANYLTHREONYLARGINYLVALYL; THREONYLGLUTAMINYLTRYPTOPHYLTHREONYLSERYLCYSTEINYLSERYLLYSYL THREONYLCYSTEINYLASPARAGINYLSERYLGLYCYLTHREONYLGLUTAMINYLSERYL ARGINYLHISTIDYLARGINYL; THREONYLGLUTAMYLTRYPTOPHYLSERYLALANYLCYSTEINYLASPARAGINYLVALYL ARGINYLCYSTEINYLGLYCYLARGINYLGLYCYLTRYPTOPHYLGLUTAMINYLLYSYLARGINYLSERYLARGINYL; THREONYLGLUTAMYLTRYPTOPHYLSERYLALANYLCYSTEINYLSERYLLYSYL THREONYLCYSTEINYLGLYCYLMETHIONYLGLYCYLISOLEUCYLSERYLTHREONYLARGINYLVALYL; THREONYLGLUTAMYLTRYPTOPHYLSERYLVALYLCYSTEINYLASPARAGINYLSERYLARGINYL CYSTEINYLGLYCYLARGINYLGLYCYLTYROSYLGLUTAMINYLLYSYLARGINYLTHREONYLARGINYL; THREONYLGLUTAMYLTRYPTOPHYLTHREONYLALANYLCYSTEINYLSERYLLYSYLSERYL CYSTEINYLGLYCYLMETHIONYLGLYCYLPHENYLALANYLSERYLTHREONYLARGINYLVALYL; THREONYLLYSYLTRYPTOPHYLTHREONYLPROLYLCYSTEINYLSERYLARGINYL THREONYLCYSTEINYLGLYCYLMETHIONYLGLYCYLISOLEUCYLSERYLASPARAGINYLARGINYLVALYL; THREONYLSERYLTRYPTOPHYLSERYLGLUTAMINYLCYSTEINYLSERYLLYSYLTHREONYL CYSTEINYLGLYCYLTHREONYLGLYCYLISOLEUCYLSERYLTHREONYLARGINYLVALYL; THROMBOSPONDIN 1; UNCLASSIFIED DRUG; WISPOSTATIN 2; WISPOSTATIN 3;

AMINO ACID SEQUENCE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CLUSTER ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG MECHANISM; DRUG SYNTHESIS; ENDOTHELIUM CELL; GENE INACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; NUCLEOTIDE SEQUENCE; PROTEIN MOTIF; UMBILICAL VEIN;

AMINO ACID SEQUENCE; ANGIOGENESIS INHIBITORS; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CLUSTER ANALYSIS; COMPLEMENT C6; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; HUMANS; IMMEDIATE-EARLY PROTEINS; IMMUNOGLOBULINS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; RECEPTORS, CELL SURFACE; SEQUENCE HOMOLOGY, AMINO ACID; THROMBOSPONDIN 1; THROMBOSPONDINS; TRANSCRIPTION FACTORS;

EID: 34748905971     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2007.06.018     Document Type: Article

References (49)

1. Adams J.C., and Tucker R.P. The thrombospondin type 1 repeat (TSR) superfamily: diverse proteins with related roles in neuronal development. Dev Dyn 218 2 (2000) 280-299
2. Albig A.R., and Schiemann W.P. Fibulin-5 antagonizes vascular endothelial growth factor (VEGF) signaling and angiogenic sprouting by endothelial cells. DNA Cell Biol 23 6 (2004) 367-379
3. Apte S.S. A disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motifs: the ADAMTS family. Int J Biochem Cell Biol 36 6 (2004) 981-985
4. Babic A.M., Kireeva M.L., Kolesnikova T.V., and Lau L.F. CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth. Proc Natl Acad Sci USA 95 11 (1998) 6355-6360
5. Brigstock D.R. Regulation of angiogenesis and endothelial cell function by connective tissue growth factor (CTGF) and cysteine-rich 61 (CYR61). Angiogenesis 5 3 (2002) 153-165
6. Brigstock D.R. The CCN family: a new stimulus package. J Endocrinol 178 2 (2003) 169-175
7. Calzada M.J., Annis D.S., Zeng B., Marcinkiewicz C., Banas B., Lawler J., et al. Identification of novel beta1 integrin binding sites in the type 1 and type 2 repeats of thrombospondin-1. J Biol Chem 279 40 (2004) 41734-41743
8. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 438 7070 (2005) 932-936
9. Carpizo D., and Iruela-Arispe M.L. Endogenous regulators of angiogenesis - emphasis on proteins with thrombospondin - type I motifs. Cancer Metast Rev 19 1-2 (2000) 159-165
10. Celik I., Surucu O., Dietz C., Heymach J.V., Force J., Hoschele I., et al. Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve. Cancer Res 65 23 (2005) 11044-11050
11. Chlenski A., Liu S., Baker L.J., Yang Q., Tian Y., Salwen H.R., et al. Neuroblastoma angiogenesis is inhibited with a folded synthetic molecule corresponding to the epidermal growth factor-like module of the follistatin domain of SPARC. Cancer Res 64 20 (2004) 7420-7425
12. Clamp M., Cuff J., Searle S.M., and Barton G.J. The Jalview Java alignment editor. Bioinformatics 20 3 (2004) 426-427
13. Dawson D.W., Pearce S.F., Zhong R., Silverstein R.L., Frazier W.A., and Bouck N.P. CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol 138 3 (1997) 707-717
14. Dawson D.W., Volpert O.V., Pearce S.F., Schneider A.J., Silverstein R.L., Henkin J., et al. Three distinct d-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat. Mol Pharmacol 55 2 (1999) 332-338
15. Farinelle S., Malonne H., Chaboteaux C., Decaestecker C., Dedecker R., Gras T., et al. Characterization of TNP-470-induced modifications to cell functions in HUVEC and cancer cells. J Pharmacol Toxicol Meth 43 1 (2000) 15-24
16. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1 1 (1995) 27-31
17. Folkman J. Endogenous inhibitors of angiogenesis. Harvey Lect 92 (1996) 65-82
18. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29 6 Suppl. 16 (2002) 15-18
19. Folkman J. Endogenous angiogenesis inhibitors. Apmis 112 7-8 (2004) 496-507
20. Gallagher W.M., Currid C.A., and Whelan L.C. Fibulins and cancer: friend or foe?. Trends Mol Med 11 7 (2005) 336-340
21. Greenwalt D.E., Lipsky R.H., Ockenhouse C.F., Ikeda H., Tandon N.N., and Jamieson G.A. Membrane glycoprotein CD36: a review of its roles in adherence, signal transduction, and transfusion medicine. Blood 80 5 (1992) 1105-1115
22. Guo N., Krutzsch H.C., Inman J.K., and Roberts D.D. Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells. Cancer Res 57 9 (1997) 1735-1742
23. Guo Y., Mazar A.P., Lebrun J.J., and Rabbani S.A. An antiangiogenic urokinase-derived peptide combined with tamoxifen decreases tumor growth and metastasis in a syngeneic model of breast cancer. Cancer Res 62 16 (2002) 4678-4684
24. Haviv F., Bradley M.F., Kalvin D.M., Schneider A.J., Davidson D.J., Majest S.M., et al. Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: design, synthesis, and optimization of pharmacokinetics and biological activities. J Med Chem 48 8 (2005) 2838-2846
25. Inadera H., Hashimoto S., Dong H.Y., Suzuki T., Nagai S., Yamashita T., et al. WISP-2 as a novel estrogen-responsive gene in human breast cancer cells. Biochem Biophys Res Commun 275 1 (2000) 108-114
26. Iruela-Arispe M.L., Luque A., and Lee N. Thrombospondin modules and angiogenesis. Int J Biochem Cell Biol 36 6 (2004) 1070-1078
27. Iruela-Arispe M.L., Vazquez F., and Ortega M.A. Antiangiogenic domains shared by thrombospondins and metallospondins, a new family of angiogenic inhibitors. Ann NY Acad Sci 886 (1999) 58-66
28. Ishiyama M., Tominaga H., Shiga M., Sasamoto K., Ohkura Y., and Ueno K. A combined assay of cell viability and in vitro cytotoxicity with a highly water-soluble tetrazolium salt, neutral red and crystal violet. Biol Pharm Bull 19 11 (1996) 1518-1520
29. Karagiannis E.D., and Popel A.S. Identification of novel short peptides derived from the α4, α5 and α6 fibrils of type IV collagen with anti-angiogenic properties. Biochem Biophys Res Commun. 354 2 (2007) 434-439
30. Krutzsch H.C., Choe B.J., Sipes J.M., Guo N., and Roberts D.D. Identification of an alpha(3)beta(1) integrin recognition sequence in thrombospondin-1. J Biol Chem 274 34 (1999) 24080-24086
31. Lawler J. Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med 6 1 (2002) 1-12
32. Lin C.G., Leu S.J., Chen N., Tebeau C.M., Lin S.X., Yeung C.Y., et al. CCN3 (NOV) is a novel angiogenic regulator of the CCN protein family. J Biol Chem 278 26 (2003) 24200-24208
33. Lopes N., Gregg D., Vasudevan S., Hassanain H., Goldschmidt-Clermont P., and Kovacic H. Thrombospondin 2 regulates cell proliferation induced by Rac1 redox-dependent signaling. Mol Cell Biol 23 15 (2003) 5401-5408
34. Lu X., Le Noble F., Yuan L., Jiang Q., De Lafarge B., Sugiyama D., et al. The netrin receptor UNC5B mediates guidance events controlling morphogenesis of the vascular system. Nature 432 7014 (2004) 179-186
35. McLachlan G.J. Cluster analysis and related techniques in medical research. Stat Meth Med Res 1 1 (1992) 27-48
36. Meiniel A., Meiniel R., Goncalves-Mendes N., Creveaux I., Didier R., and Dastugue B. The thrombospondin type 1 repeat (TSR) and neuronal differentiation: roles of SCO-spondin oligopeptides on neuronal cell types and cell lines. Int Rev Cytol 230 (2003) 1-39
37. Nyberg P., Xie L., and Kalluri R. Endogenous inhibitors of angiogenesis. Cancer Res 65 10 (2005) 3967-3979
38. O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88 2 (1997) 277-285
39. Porter S., Clark I.M., Kevorkian L., and Edwards D.R. The ADAMTS metalloproteinases. Biochem J 386 Pt 1 (2005) 15-27
40. Reiher F.K., Volpert O.V., Jimenez B., Crawford S.E., Dinney C.P., Henkin J., et al. Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics. Int J Cancer 98 5 (2002) 682-689
41. Ren B., Yee K.O., Lawler J., and Khosravi-Far R. Regulation of tumor angiogenesis by thrombospondin-1. Biochim Biophys Acta 1765 2 (2006) 178-188
42. Romesburg H.C. Cluster analysis for researchers (1984), Lifetime Learning Publications, Belmont, California
43. Sage E.H., Reed M., Funk S.E., Truong T., Steadele M., Puolakkainen P., et al. Cleavage of the matricellular protein SPARC by matrix metalloproteinase 3 produces polypeptides that influence angiogenesis. J Biol Chem 278 39 (2003) 37849-37857
44. Shimo T., Nakanishi T., Nishida T., Asano M., Kanyama M., Kuboki T., et al. Connective tissue growth factor induces the proliferation, migration, and tube formation of vascular endothelial cells in vitro, and angiogenesis in vivo. J Biochem (Tokyo) 126 1 (1999) 137-145
45. Short S.M., Derrien A., Narsimhan R.P., Lawler J., Ingber D.E., and Zetter B.R. Inhibition of endothelial cell migration by thrombospondin-1 type-1 repeats is mediated by beta1 integrins. J Cell Biol 168 4 (2005) 643-653
46. Thompson J.D., Higgins D.G., and Gibson T.J. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 22 22 (1994) 4673-4680
47. Tjin Tham Sjin R.M., Satchi-Fainaro R., Birsner A.E., Ramanujam V.M., Folkman J., and Javaherian K. A 27-amino-acid synthetic peptide corresponding to the NH2-terminal zinc-binding domain of endostatin is responsible for its antitumor activity. Cancer Res 65 9 (2005) 3656-3663
48. Tolsma S.S., Volpert O.V., Good D.J., Frazier W.A., Polverini P.J., and Bouck N. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J Cell Biol 122 2 (1993) 497-511
49. Vazquez F., Hastings G., Ortega M.A., Lane T.F., Oikemus S., Lombardo M., et al. METH-1, a human ortholog of ADAMTS-1, and METH-2 are members of a new family of proteins with angio-inhibitory activity. J Biol Chem 274 33 (1999) 23349-23357